Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

BACKGROUND: Increased risk of cardiovascular events is associated not only with dyslipidemias, but also with abnormalities in glucose metabolism and liver function. This study uses pooled analysis to explore the in-depth effects of pemafibrate, a selective peroxisome proliferator-activated receptor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovasc Diabetol
Hauptverfasser: Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2021
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8097867/
https://ncbi.nlm.nih.gov/pubmed/33947390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01291-w
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge